Company news
Everest Medicines Ltd. (HKEX:1952) news
Everest Medicines Ltd. news releases on 6ix. Latest, Sep 28, 2026: TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE
Press releases & updates
TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE
September 28, 2026
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
September 28, 2026
ESTABLISHMENT OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE
September 28, 2026
Next Day Disclosure Return
September 28, 2026
Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
September 3, 2026
Everest Medicines Announces Interim Results for First Half of 2026
August 18, 2026
Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
August 5, 2026
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
July 7, 2026
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
June 25, 2026
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
June 24, 2026
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
June 8, 2026
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
June 4, 2026
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 2, 2026
Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited
April 7, 2026
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
March 30, 2026
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
March 22, 2026
Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited
March 17, 2026
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
March 16, 2026
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
March 13, 2026
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026
March 10, 2026
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
March 9, 2026
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis
February 6, 2026
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
February 4, 2026
Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
December 17, 2025
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
December 14, 2025
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
December 11, 2025
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
November 20, 2025
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
October 30, 2025
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
October 29, 2025
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
October 16, 2025
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
October 14, 2025
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
October 12, 2025
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
October 9, 2025
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
September 14, 2025
Everest Medicines Announces Interim Results for First Half of 2025
August 28, 2025
Everest Medicines Announces Participation in September Investor Conferences
August 25, 2025
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
August 15, 2025
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
August 14, 2025
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
August 14, 2025
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
August 11, 2025
Everest Medicines Announces Full Approval of NEFECON® in Taiwan
August 6, 2025
Everest Medicines Expands Strategic Investment in I-MAB
August 1, 2025
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
July 24, 2025
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
July 4, 2025
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
July 2, 2025
Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025
June 26, 2025
Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)
June 22, 2025
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
June 20, 2025
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
June 9, 2025